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Background: Bipolar disorder (BD) is a chronic, relapsing, episodic mental illness associated 
with other psychiatric comorbidities. There is a substantial economic burden with BD, which 
makes it challenging to treat. The aim of this review is to evaluate the pharmacology, clinical 
efficacy, and safety data related to paliperidone extended release (ER) for the treatment of BD.
Methods: A literature search was performed from January 1966 through January 2012 using 
  PreMEDLINE, MEDLINE, EMBASE, IPA, and ClinicalTrials.gov to identify articles in English 
regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or 
mixed episodes or in the maintenance treatment of BD I.
Results: There are currently three published studies relating to the use of paliperidone ER for 
the treatment of BD. Two of these evaluated paliperidone ER as monotherapy for acute mania, 
while the other assessed its role as adjunct with a mood stabilizer.
Conclusion: According to the limited available evidence, paliperidone at higher doses of ER 
9–12 mg/day may be a safe and efficacious treatment option for acute episodes of mania in BD. 
A once-daily dose formulation may improve patient adherence to treatment; however, the cost 
of paliperidone ER, which is higher than that of generically available second-generation antip-
sychotics (such as olanzapine and risperidone), and a lack of alternative dosage forms (ie, liquid, 
intramuscular) compared with other agents may limit its usefulness in the treatment of BD. The role 
of paliperidone ER as an adjunctive agent or for long-term use requires further investigation.
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Background
Bipolar disorder (BD) is a chronic, episodic mental illness characterized by periods 
of mania, depression, and mixed episodes with an estimated lifetime prevalence of 
approximately 1%.1 The mean age of onset is 18–20 years, that is, in the late teens 
to early adulthood.2 According to the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision (DSM-IV-TR), patients presenting with a 
manic episode must have an abnormally and persistently elevated or expansive mood 
for 1 week, or for any duration if the patient is hospitalized.3 In addition, the patient 
must have symptoms such as racing thoughts, distractibility, and inflated self-esteem 
or grandiosity. In severe cases, patients may have psychotic symptoms (eg, auditory 
hallucinations, delusions). Patients with BD often have other comorbidities, including 
anxiety and alcohol use as well as other substance abuse disorders, which makes 
treatment challenging for health care providers.4,5 Previous evidence has shown that 
clinical factors such as the presence of anxiety and alcohol use are associated with 
nonadherence to bipolar medications, and that these factors may also contribute to 
hypomanic or manic episodes.6
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Current consensus guidelines recommend pharmaco-
therapy as first-line treatment for patients.7–9 A summary of 
US Food and Drug Administration (FDA)-approved agents 
for BD is listed in Table 1. Lithium, valproate, or second-
generation antipsychotics (SGAs) represent first-line options, 
with valproate being preferred over lithium for mixed 
episodes.7,8 Combination therapy, consisting of different 
pharmacologic classes, can be implemented in severe cases. 
Overall, SGAs are equally, if not more, effective than lithium 
and valproate for the acute treatment of mania. This was 
recently confirmed in a meta-analysis that systematically 
reviewed 68 randomized controlled trials of mood stabilizers 
and antipsychotics in the treatment of mania.10 The main 
outcome of the study was to assess the mean change of the 
Young Mania Rating Scale (YMRS) over 3 weeks as well 
as treatment discontinuation rates. Overall, antipsychotics 
tended to be more efficacious and had fewer discontinuations 
compared with mood stabilizers.
Although there are several treatment options targeting 
manic symptoms, reported relapse and recurrence rates 
range from 39% to 52% per year with varying medication 
regimens.11 Nonadherence to medication also has a 
substantial impact on patient outcome and recovery. A study 
reported that 10%–60% of patients with mood disorders 
are nonadherent to treatment, which is possibly related 
to medication side effects.12 Conversely, those who are 
adherent with medications may develop untoward side effects 
associated with chronic use, including weight gain, metabolic 
disturbances, and movement disorders.13 As a result, 
it is necessary to seek new agents that are well tolerated to 
improve patient adherence and overall outcomes.
The aim of this review is to evaluate the pharmacology, 
safety, and efficacy of paliperidone extended release (ER) 
for the treatment of BD. Paliperidone (9-OH-risperidone) 
is an SGA currently FDA approved for the treatment of 
schizophrenia and schizoaffective disorder. Paliperidone 
has the potential to treat the manic symptoms of BD. It is 
the major active metabolite of risperidone and it has many 
similarities with its parent compound that may contribute to 
potential efficacy in the treatment of manic episodes in BD. 
Additionally, paliperidone appears to have fewer side effects 
than risperidone, which may improve patient adherence.
Methods
A literature search was performed from January 1966 to 
January 2012 using PreMEDLINE, MEDLINE, EMBASE, 
IPA, and ClinicalTrials.gov databases, to identify articles in 
English regarding the pharmacology, clinical efficacy, and 
safety of paliperidone ER in acute mania or mixed episodes, 
or maintenance treatment of BD I. Full text articles and 
abstracts were evaluated and included in the review if they 
were relevant to our topic.
Table 1 Medications FDA approved for bipolar disorder
Pharmacologic class and medication FDA-approved indications
Acute mania Acute depression Mixed symptoms Maintenance   
treatment
Group 1A alkaline metals
Lithium a a
First-generation antipsychotics
Chlorpromazine b
Second-generation antipsychotics
Olanzapine c  
Olanzapine/Fluoxetine combination a
Risperidone c c
Risperidone long-acting intramuscular injection a
Quetiapine (immediate release and extended release) c a c d
Ziprasidone a a d
Aripiprazole c c c
Asenapine c c
Antiepileptic medications
Lamotrigine a
Divalproex (immediate release and extended release) a a
Carbamazepine extended release a a
Notes: aFDA approved as a monotherapy; bFDA approved to control the manifestations of the manic type of manic-depressive illness; cFDA approved as a monotherapy or 
as an adjunct treatment to lithium or valproate; dFDA approved only as an adjunct to lithium or divalproex sodium for maintenance.
Abbreviation: FDA, US Food and Drug Administration.
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Chemistry
Paliperidone is the major active metabolite of risperidone. 
It is a benzisoxazole derivative chemically known as (+/−)-3[2-
[4-(6-flouro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-
6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]
pyrimidin-4-one.14 Insoluble in water, paliperidone has a 
molecular formula and weight of C23H27FN4O3, and 426.49, 
respectively.
Pharmacology
Paliperidone’s primary mechanism of action is via potent 
inhibition of dopamine (D2) receptors and is a partial sero-
tonergic (5-HT2A) antagonist. It also has an affinity for several 
  additional receptors, including 5-HT1D, 5-HT2B, 5-HT7, and 
D3.15–17 The Ki values for binding to D2 and 5HT2A receptors 
are 0.16 and 0.25 nM, respectively.15,16,18 In vitro studies show 
a weak affinity for alpha (α1,2) adrenergic and histaminic 
(H1) receptors while displaying no affinity for cholinergic, 
muscarinic, or beta (β1,2) adrenergic receptors.17 As a result, 
in vitro data suggest a lower risk of orthostasis, sedation, and 
weight gain compared with other SGAs (eg, olanzapine). 
A 6 mg dose of paliperidone in humans provides a striatal 
D2 occupancy of 64% and 53% after 22 and 46 hours, 
respectively.19 Occupancy for the 5-HT2A receptor is 65% 
and plasma concentrations range between 5.1 and 6.0 ng/mL 
over 4 hours.19 As a result, a 6 mg dose appears to provide 
sufficient receptor binding in its ability to effectively treat 
symptoms of mania or psychosis.20
Animal data show that paliperidone has protein 
expression profiles at the neuronal level (ie, synapse) that 
is most similar to lithium, an agent considered first line 
in the treatment of BD.21 Paliperidone appears to inhibit 
glycogen synthase kinase 3 in the pre-frontal cortex, which 
may account for its mood stabilizing effects. Additionally, 
like lithium, paliperidone demonstrates activity on 
oxidative phosphorylation, electron transport, carbohydrate 
metabolism, and postsynaptic cytokinesis.21 As a result, based 
on in vitro studies, it has been determined that paliperidone 
may play a role in signaling pathways, energy metabolism, 
and synaptic plasticity, which may be implicated in BD.
Pharmacokinetics
Absorption and distribution
Overall, the absolute bioavailability of paliperidone is 28%, 
with a volume of distribution of approximately 490 L. The 
elimination half-life (t½) is 23 hours and time to steady state 
occurs in approximately 4–5 days. Paliperidone is delivered 
via Osmotic-controlled Release Oral Delivery System 
technology, which slowly delivers paliperidone over 24 hours 
with minimal peak to trough fluctuations.14,22 Peak plasma 
concentrations and time to peak plasma concentrations are 
11 ng/mL and 24 hours, respectively.19 Presently, even though 
the package insert states paliperidone can be taken irrespective 
of meals, it appears food increases the bioavailability of 
paliperidone. Unpublished data demonstrate food increases 
peak plasma concentrations and area under the curve 
(AUC) by 60% and 54%, respectively.14 Paliperidone is 
approximately 74% protein bound and the total volume of 
distribution is approximately 485 L. The enantiomers of 
paliperidone interconvert and are equipotent.23,24
Metabolism and elimination
Only 32% of paliperidone is recovered as metabolites 
through cytochrome P450 (CYP) 2D6, and to a lesser extent, 
CYP 3A4. The pharmacokinetic profile of paliperidone is 
similar in subjects with normal hepatic function and moderate 
hepatic impairment.25 Therefore, dose adjustments are not 
needed for those with mild to moderate hepatic function. 
At this time, studies evaluating patients with severe hepatic 
impairment are lacking, and caution may be warranted in 
this patient population. Additionally, differences in adverse 
effects (ie, extrapyramidal symptoms [EPS]) between 
poor and extensive metabolizers of CYP 2D6 appear to be 
minimal; therefore, dose adjustments of paliperidone are 
also not required.26 Impaired renal function may increase 
paliperidone concentrations since 60% of the drug is excreted 
almost unchanged in the urine via the renal tubules.14,22 
As a result, patients with a creatinine clearance rate 
(CrCl) $50 mL/min should be initiated at 6 mg daily, while 
those with CrCl , 50 mL/min should be started at 3 mg daily.14 
The dosing   recommendations are based on data that show the 
total clearance of paliperidone decreases by 32%, 64%, and 
71% in those with mild (CrCL 50 to ,80 mL/min), moderate 
(CrCl 30 to ,50 mL/min), and severe (CrCl , 30 mL/min) 
renal impairment, respectively.14
Special populations
Pharmacokinetics have been evaluated in the elderly 
population (mean age: 71 ± 5.1 years).27 Data after single 
and multiple dosing show some differences in the area 
under the plasma concentration–time curve (ie, AUC0–∞, 
AUCt) and t½. Additionally, clearance in the geriatric group 
was 20%–24% lower than in the adult group. Despite these 
pharmacokinetic differences, paliperidone does not merit any 
dose adjustment in geriatrics with normal kidney function. 
The pharmacokinetic profile of paliperidone in 24 children 
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aged 10–17 years was conducted in a multicenter, open-label 
study.28 Plasma concentration gradually peaked after 24 hours 
from the first dose, and a steady state was achieved at day 4 
or 5. The pharmacokinetic profiles of adults and pediatrics 
appear to be similar.28
Drug interactions
Trials evaluating pharmacokinetic drug–drug interactions 
are limited. One randomized, crossover, open label study in 
healthy males assessed the drug interaction potential between 
paliperidone and paroxetine, a potent CYP 2D6 inhibitor.29 
The AUC and t½ of paliperidone were minimally increased 
and not clinically significant. However, it must be noted 
that low doses of paliperidone (3 mg) and paroxetine 
(20 mg) were administered during the study. Therefore, 
it is unknown if normal daily doses of these agents would 
  generate more   significant findings. A possible interaction 
between divalproex sodium and paliperidone may occur. 
There was a 50% increase in paliperidone (12 mg daily) 
peak plasma concentrations and AUC concentrations when 
taken concomitantly with divalproex sodium extended 
release (1000 mg daily).14 Additionally, data show that 
carbamazepine (400 mg daily) can decrease paliperidone 
(6 mg daily)   concentrations by approximately 35%. Therefore, 
paliperidone dose adjustment is needed when adding or 
  discontinuing divalproex sodium or carbamazepine.
Paliperidone is mostly excreted via the renal tubules 
through a cation transport system. Other drugs that are also 
excreted through this mechanism (eg, ketoconazole, lithium) 
may compete with the transport site. Therefore, concomitant 
administration may cause a reduction in the clearance and 
an increase in AUC of any of these agents. In one trial, renal 
clearance of paliperidone was assessed when taken alone or 
in combination with trimethoprim (200 mg twice daily).30 
The open-label, randomized, cross-over study showed an 
insignificant decrease in concentration (ie, AUC0–∞) and 
a 5-hour decrease in the t½ of paliperidone; however, the 
results did not warrant any dose adjustments. When   compared 
with risperidone, in vitro data appear to demonstrate that 
paliperidone is a weak inhibitor of P-glycoprotein (P-gp). As 
a result, lower paliperidone concentrations in cerebrospinal 
fluid may occur. However, caution interpreting these 
results is warranted since varying concentrations may affect 
  paliperidone and P-gp interactions.
Paliperidone versus risperidone
Risperidone is FDA approved for the treatment of BD based 
on clinical data demonstrating efficacy. Since   paliperidone is 
the active metabolite of risperidone, it would seem logical that 
paliperidone would demonstrate efficacy as well. However, 
paliperidone and risperidone have some pharmacodynamic 
differences that could affect efficacy in treatment of BD. 
First, paliperidone may have more difficulty compared 
with risperidone in crossing into the central nervous system 
(eg, blood–brain barrier).31 Additionally, paliperidone has a 
greater affinity for D2 receptors and a lower affinity for 5-HT2a 
receptors compared with risperidone. As a result, the data 
suggest paliperidone acts less as an atypical antipsychotic 
(eg, showing improvements in mood and cognition) compared 
to risperidone. On the contrary, paliperidone may offer some 
advantages over risperidone. Studies evaluating receptor 
affinity suggest that paliperidone may have a lower incidence 
of orthostatic hypotension and may cause lower weight gain 
compared with risperidone.31 Additionally, paliperidone may 
have a more favorable dosing profile (eg, less titration) and 
linear kinetics (eg, once-daily dosing); however, risperidone 
given twice daily would offer lower peak concentrations, 
which may lead to fewer adverse effects. Comparative studies 
are needed to confirm whether paliperidone is as equally safe 
and effective as risperidone in treating patients with BD.
Clinical efficacy studies
Paliperidone ER is not currently FDA labeled for BD; 
however, to date, there have been three published randomized 
controlled studies evaluating the efficacy and safety of 
treating adult patients with BD. Two of these evaluated 
paliperidone ER as monotherapy and the other assessed 
adjunctive therapy.32–34 A summary of these studies is found 
in Table 2. The primary outcome was change of YMRS from 
baseline to endpoint in all of the studies. Further, secondary 
outcomes included changes in Global Assessment of 
Functioning, as well as response (defined as $50% reduction 
in YMRS total score), remission rates (defined as YMRS 
score of #12 at endpoint), and adverse effects. Of note is that 
all these published studies were industry-sponsored trials.
Monotherapy
Berwaerts et al conducted a 3-week, double-blind, placebo-
controlled, dose–response study in adult patients (n = 443; 
mean [standard deviation (SD)] age: 39 (10.9); 53% males) 
with a DSM-IV-TR diagnosis of BD I, most recent episode of 
mania or mixed mania.32 The study included a 7-day washout 
period, followed by 3 weeks of double-blind treatment and 
a 1-week follow-up for safety assessments. Participants 
were randomized to receive either paliperidone ER 3, 6, or 
12 mg/day or placebo. Patients receiving paliperidone ER 
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12 mg had significant improvements in mean (SD) YMRS 
total score at the endpoint compared with placebo (−13.8 
[9.67] vs −9.8 [10.60]; P , 0.025) based on last observation 
carried forward analysis. No other treatment group (3 or 
6 mg) showed significant improvements in YMRS total 
score compared to the placebo. Additionally, there were no 
statistical improvements in any of the secondary outcome 
measures compared to the placebo (ie, response, remission 
rates). According to the study, it appears that paliperidone ER 
12 mg is an effective dose for treating acute mania. However, 
the comparable placebo response may have resulted in a lack 
of efficacy with the lower doses.
Another study evaluated the efficacy and safety of 
  paliperidone ER in a 12-week randomized, placebo and 
active control study with quetiapine in adult patients (n = 486; 
mean [SD] age 39 years [10.9]; 58% males) with a DSM-
IV-TR diagnosis of acute manic or mixed episodes of BD.33 
There was a 1-week washout period, followed by a 3-week 
double-blind phase in which patients received flexible dosing 
of paliperidone ER, at 3–12 mg/day. A 9-week double-blind 
maintenance phase was continued, where patients either con-
tinued flexible dosing with their active treatment or switched 
from the placebo to paliperidone ER 6 mg. Paliperidone ER 
was initiated at 6 mg/day and titrated or tapered in 3 mg 
increments with a maximum dose of 12 mg/day as clinically 
necessary. Quetiapine was initiated at 100 mg/day on day 1 
and forced titration to 400 mg/day at day 4, with adjustments 
of 200 mg/day to a maximum of 800 mg/day. Median doses 
were 9 mg for the paliperidone ER group and 600 mg for the 
quetiapine group during the 3-week phase.
Based on the last-observation-carried-forward analysis, 
at the end of 3 weeks, paliperidone ER-treated patients had 
a significant mean reduction in least square means (LSM) 
YMRS total score compared with the placebo group (LSM 
difference from placebo was −5.5; 95% CI −7.57, −3.35; 
P , 0.001). At the end of 12 weeks, LSM for changes in 
YMRS total score between quetiapine and paliperidone ER 
was −1.7 (95% CI −0.47, 3.96). The lower limit of 95% CI 
(−0.47) was greater than the noninferiority margin of −4, 
so paliperidone ER was considered noninferior to quetiap-
ine in this study. Additionally, mean (SD) change in Global 
Assessment of Functioning scores was significantly improved 
in the paliperidone ER group (12.2 [11.1] compared with the 
placebo (6.7 [13.5] at 3 weeks (P , 0.001). There was a higher 
percentage of remitters in the paliperidone ER-treated group 
compared with the placebo at 3 weeks (52% [99/190] vs 28% 
[30/104], P , 0.001). As a result, it appears that paliperidone 
ER 3–12 mg is as effective as quetiapine for the treatment of 
acute mania; however, the higher doses may be more effective, 
as the median dose was 9 mg.
Adjunct treatment
A 6-week, randomized, placebo-controlled study evaluating 
paliperidone ER as adjunct to lithium or valproate was 
conducted in adult patients (n = 299; mean (SD) age 40 
[11] years, 54% males) with acute mania.34 Inclusion criteria 
included a DSM-IV-TR diagnosis of BD I, with either a recent 
episode of mania or mixed mania without psychosis and 
treatment with lithium or valproate for BD $ 2 weeks prior 
to randomization. The study consisted of a 14-day washout 
Table 2 Summary of clinical studies with paliperidone extended release in acute mania32–34
Study N Change in mean (SD)  
YMRS total score
Difference in LS mean changea
95% CI P value
Monotherapy
Berwaerts et al32 443
  Paliperidone ER 3 mg 107 −9.1 (11.18) −1.0 (−1.59, 3.58) 0.79
  Paliperidone ER 6 mg 112 −11.4 (9.98) −1.4 (−3.98, 1.15) 0.57
  Paliperidone ER 12 mg 109 −13.8 (9.67)b −3.6 (−6.99, 0.30) 0.025
  Placebo 115 −9.8 (10.60)
Vieta et al33 486
  Paliperidone ER 3–12 mg 190 −13.2 (8.68) −5.5 (−7.57, 3.35) 0.001
  Quetiapine 400–800 mg 192 −11.7 (9.28) −4.2 (6.45, −1.95) 0.001
  Placebo 104 −7.4 (10.74)
Adjunct
Berwaerts et al34 299
  Paliperidone ER plus MS 149 −14.3 (10.01) −1.36 (−3.27, 0.54) 0.16
  MS monotherapy plus placebo 150 −13.2 (10.91)
Notes: aAll least square means change versus placebo, except Berwaerts et al adjunctive study: combo vs monotherapy; bP value = 0.005.
Abbreviations: CI, confidence interval; ER, extended release; LS, least squares; MS, mood stabilizer (lithium or valproate); SD, standard deviation; YMRS, Young Mania 
Rating Scale.
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period, followed by a 6-week double-blind phase, with a 
1-week follow-up. Participants were randomized to either 
continue monotherapy (n = 150) with lithium or valproate, 
or receive adjunctive paliperidone ER (n = 149) at a flexible 
dose (3–12 mg/day). Based on the intention-to-treat last-
observation-carried-forward analysis, patients who received 
combination treatment (median dose: 6 mg/day) had no 
significant differences in mean change in YMRS score from 
baseline (LSM difference, 95% CI: −1.36 [−3.27, 0.54]; 
P = 0.16). Additionally, there were no differences in Global 
Assessment of Functioning scores (LSM difference, 95% 
CI: 2.47 [−0.93, 5.87]; P = 0.15). The authors did not report 
valproate or lithium doses and serum concentrations, and 
most patients received valproate at baseline (63% [94/150]). 
Although there were no benefits in adding paliperidone ER 
to a mood stabilizer for patients with acute mania, caution is 
warranted when evaluating the results, as these patients may 
have needed a higher dose for improvement in symptoms.
Safety and tolerability
Tolerability data pertaining to paliperidone ER in patients 
with BD were obtained from three double-blind clinical 
trials.32–34 Adverse events related to paliperidone ER in 
the bipolar studies are generally consistent with adverse 
events seen in other populations treated with paliperidone 
in former clinical studies (eg, schizophrenia, schizoaffective 
disorder).35 The treatment-emergent adverse events (TEAEs) 
associated with paliperidone ER in the three clinical trials 
are summarized in Table 3.
Paliperidone ER was generally well tolerated in the two 
3-week acute monotherapy phase trials.32,33 Treatment emer-
gent adverse events were similar among paliperidone ER 
and the placebo in the 3-week fixed-dose trial; however, the 
frequency of adverse events increased as the dose of paliperi-
done ER increased. Excluding EPS-related adverse events, 
the TEAEs most commonly reported ($5% of all paliperi-
done ER recipients) were headache, insomnia, somnolence, 
sedation, dizziness, constipation, nausea, vomiting, dys-
pepsia, and mania. Mood switches to depression were not 
significantly different between paliperidone ER groups and 
the placebo group.32
In the monotherapy trial using quetiapine as an active 
comparator, TEAEs were slightly higher in the quetiapine 
treatment group (77%) versus the paliperidone ER (65%) 
and placebo groups (63%) during the 3-week acute treatment 
phase.33 Excluding EPS-related adverse events, the TEAEs 
most commonly reported ($5% of all paliperidone ER 
recipients) in the acute phase of treatment were headache, 
insomnia, somnolence, sedation, dizziness, constipation, 
dyspepsia, dry mouth, and insomnia. Similar trends were 
seen in the continuous 9-week maintenance phase, with 
similar TEAEs occurring in both the placebo/paliperidone 
ER group (71%) and paliperidone ER group (71%). Slightly 
higher TEAEs were reported with the quetiapine treatment 
group (82%) at the end of the maintenance phase. One 
death was reported in the maintenance phase (quetiapine 
treatment group) and another death was reported 5 days 
after withdrawal from the maintenance phase of the 
Table 3 Treatment-emergent adverse events (TEAEs) during double-blind controlled trials of paliperidone extended release (ER) for 
bipolar disorder32–34
Overall  
TEAEs
Possibly  
related TEAEs
TEAEs  
leading to death
1 or more  
serious TEAEs
TEAEs leading  
to discontinuation
Monotherapy
Berwaerts et al32
  Placebo (n = 121) n (%) 85 (70) 49 (40) 0 10 (8) 6 (5)
  Paliperidone ER 3 mg (n = 112) n (%) 68 (61) 45 (40) 0 4 (4) 1 (1)
  Paliperidone ER 6 mg (n = 119) n (%) 89 (75) 64 (54) 0 5 (4) 13 (11)
  Paliperidone ER 12 mg (n = 115) n (%) 100 (87) 68 (59) 0 5 (4) 9 (8)
  Total (n = 467) n (%) 342 (73) 226 (48) 0 24 (5) 29 (6)
Vieta et al33
  Placebo/paliperidone ER (n = 105) n (%) 75 (71) 50 (48) 1 (1) 8 (8) 7 (7)
  Paliperidone ER (n = 194) n (%) 136 (70) 113 (58) 0 16 (8) 18 (9)
  Quetiapine (n = 192) n (%) 157 (82) 122 (64) 1 (1) 14 (7) 12 (6)
  Total (n = 491) n (%) 368 (75) 285 (58) 2 (,1) 38 (8) 37 (8)
Adjunct
Berwaerts et al34
  MS + Placebo (n = 150) n (%) 81 (54) 39 (26) NR 7 (5) 2 (1)
  MS + Paliperidone ER (n = 149) n (%) 104 (70) 62 (42) NR 7 (5) 12 (8)
Abbreviation: MS, mood stabilizer (lithium or valproate).
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study (placebo/paliperidone ER group). Both deaths were 
considered possibly related to the study drug. A mood switch 
to depression was not different in any group at the end of the 
3-week acute phase. Quetiapine therapy had significantly less 
(P = 0.044) mood switches to depression than paliperidone 
ER at the end of the maintenance phase.
Treatment with paliperidone ER as an adjunctive agent to 
lithium and valproate treatment was associated with a higher 
frequency of TEAEs (70%) compared with patients   receiving 
placebo as an adjunctive agent (54%) during the 6-week 
study.34 Excluding EPS-related adverse events, the TEAEs 
most commonly reported ($5% of all paliperidone ER 
recipients) were headache, somnolence, sedation, insomnia, 
dry mouth, weight gain, and increased appetite. The majority 
of adverse effects occurred at a higher frequency with pali-
peridone ER than with mood stabilizer monotherapy ($3% 
difference compared with monotherapy), with the exception 
of insomnia and dry mouth. A higher number of patients 
switched to depression with mood stabilizer monotherapy 
(14%) than with combination treatment (7%); however, the 
difference did not reach statistical significance.
EPS-related adverse events
EPS-related adverse events occurred more frequently in the 
paliperidone ER treatment groups in all studies. Compared 
with the placebo group, paliperidone ER treatment groups had 
higher frequencies ($3% difference) of hypertonia (3% vs 
1%), akathisia (5% vs 2%), and dystonia (4% vs 0%) in the 
3-week fixed-monotherapy trial. One patient discontinued 
treatment secondary to dystonia.32 In the 12-week main-
tenance study, EPS-related adverse events that occurred 
more frequently ($3% difference) in the paliperidone ER 
group compared to patients receiving quetiapine included 
akathisia (10% vs 3%), hypertonia (5% vs 1%), and drooling 
(6% vs 0%).33 Compared to mood stabilizer monotherapy, 
EPS-related adverse events that occurred more frequently 
with adjunctive paliperidone ER therapy ($3% difference) 
included akathisia (8% vs 1%) and extrapyramidal disorder 
(4% vs 1%). Concurrent anticholinergic therapy for treatment 
of EPS was higher with combination treatment (10%) than 
with mood stabilizer monotherapy (3%).34
Metabolic and prolactin adverse effects
The mean change in body weight from baseline in the fixed-
dose 3-week acute trial was 0.2 and 1.1 kg with placebo 
and paliperidone ER, respectively. Thirteen patients treated 
with paliperidone ER as monotherapy experienced $7% 
weight increase from baseline compared to one patient 
treated with placebo.32 The mean change in body weight 
from baseline at the 3-week endpoint in the active compara-
tor trial was 0.6, 1.1, and 1.1 kg with placebo, paliperidone 
ER, and quetiapine, respectively. At the end of the 12-week 
  maintenance phase, the mean change in body weight from 
baseline was 1.2, 1.5, and 2.0 kg for placebo/paliperidone ER, 
paliperidone ER, and quetiapine, respectively. More patients 
treated with quetiapine (17%) had $7% weight increase from 
baseline compared to the paliperidone ER group (8%) at the 
end of the maintenance phase.33 The mean weight change 
with paliperidone ER adjunctive therapy was higher (1.8 kg) 
than in mood stabilizer monotherapy (0.7 kg). Fifteen percent 
of patients treated with the combination therapy had $7% 
weight increase from baseline compared with 5% treated 
with mood stabilizer monotherapy.34
Glucose-related adverse events were rare in the bipolar 
trials. No treatment-emergent glucose-related adverse events 
were reported in the fixed-dose monotherapy study and #2% 
occurred in all treatment groups within the adjunctive and 
maintenance studies. Dose-related increases in prolactin 
concentrations were associated with paliperidone treatment in 
all studies. Mean increases in prolactin concentrations ranged 
from 13.5 to 36.0 ng/mL in men and 59.6 to 103.9 ng/mL 
in women in the three trials.32–34 A total of 17 TEAEs with 
paliperidone ER were identified across all studies, which is 
possibly related to elevated prolactin elevations, with none 
leading to study discontinuation.
Cardiac adverse events
With the exception of tachycardia, clinically relevant changes 
in vital signs or electrocardiography parameters were 
minimal in the paliperidone ER treatment groups. Twelve 
percent of patients treated with a combination of a mood 
stabilizer and paliperidone ER had abnormally high heart 
rates ($100 bpm) compared with 5% with mood stabilizer 
monotherapy.34 In the maintenance study, abnormally high 
heart rates were reported in 20% of patients treated with 
paliperidone ER monotherapy compared to 19% and 10% 
of patients treated with quetiapine and placebo/paliperidone 
ER, respectively.33 With the exception of heart rate, there 
were no clinically relevant differences in electrocardiography 
recordings between the placebo and paliperidone treatment 
groups in all three studies.32–34
Summary
Based on the limited amount of available data, paliperidone 
ER may be an effective agent for the treatment of acute 
episodes of BD at doses ranging from 9 to 12 mg/day. 
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The study evaluating lower doses of paliperidone ER 
(#6 mg) as adjunctive therapy showed that there was no 
improvement in efficacy and the addition of paliperidone 
led to a higher incidence of adverse events (eg, tachycardia). 
Common adverse effects reported in the acute trials included 
headache and sedation. A higher incidence of EPS was also 
reported with paliperidone than with quetiapine. Although 
more patients gained weight when receiving paliperidone, 
these effects were comparable to quetiapine.   Additionally, 
tachycardia was reported to occur more frequently in 
patients receiving a combination of paliperidone and a mood 
stabilizer and caution is warranted in patients with cardiac 
comorbidities.
Currently, there are no published results for pali-
peridone’s effects on preventing recurrence of BD and no 
head-to-head studies comparing paliperidone with other 
antipsychotic or mood stabilizers. At this time, paliperidone 
ER does not appear to have benefits additional to those pro-
vided by other currently approved SGAs or mood stabilizers 
for acute mania. Further study is needed, especially regard-
ing mixed or depressed episodes of BD and paliperidone’s 
potential use as a maintenance treatment. A once-daily dose 
formulation may improve patient adherence to treatment; 
however, cost, the availability of other approved generic 
SGAs (ie, olanzapine, risperidone), and a lack of other 
dosage formulation availability (ie, liquid, intramuscular) 
compared with other agents, may limit its extended use for 
the treatment of BD.
Disclosure
The authors declare no conflicts of interest in this work.
References
1.  Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month 
prevalence of bipolar spectrum disorder in the National Comorbidity 
Survey replication. Arch Gen Psychiatry. 2007;64(5):543–552.
2.  Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar 
spectrum disorder in the world mental health survey initiative. Arch Gen 
Psychiatry. 2011;68(3):241–251.
3.  American Psychiatric Association. Diagnostic and Statistical Manual 
of Mental Disorders, 4th ed. Text revision. Washington, DC: American 
Psychiatric Association; 2000.
4.  Ostacher MJ, Perlis RH, Nierenberg AA, et al. Impact of substance use 
disorders on recovery from episodes of depression in bipolar disorder 
patients: prospective data from the Systematic Treatment Enhancement 
Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2010; 
167(3):289–297.
5.  Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated 
with poor pharmacologic adherence in bipolar disorder: results from the 
STEP-BD study. J Clin Psychiatry. 2010;71(3):296–303.
6.  Perlis RH, Uher R, Ostacher M, et al. Association between bipolar 
spectrum features and treatment outcomes in outpatients with major 
depressive disorder. Arch Gen Psychiatry. 2011;68(4):351–360.
  7.  American Psychiatric Association. Practice guideline for the treatment 
of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 
159(Suppl 4):1–50.
  8.  Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas imple-
mentation of medication algorithms: update to the algorithms for 
treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7): 
870–886.
  9.  Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for 
Mood and Anxiety Treatments (CANMAT) and International Society for 
  Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines 
for the management of patients with bipolar disorder: update 2009. 
Bipolar Disord. 2009;11(3):225–255.
  10.  Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and 
acceptability of antimanic drugs in acute mania: a multiple-treatments 
meta-analysis. Lancet. 2011;378(9799):1306–1315.
  11.  Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-
Episode Mania Study: prediction of recovery and first recurrence. 
Am J Psychiatry. 2003;160(12):2099–2107.
  12.  Lingam R, Scott J. Treatment non-adherence in affective disorders. 
Acta Psychiatr Scand. 2002;105(3):164–172.
  13.  Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. 
Dialogues Clin Neurosci. 2008;10(2):165–179.
  14.  InvegaTM (paliperidone) extended-release tablets [package insert]. 
Titusville, NJ; 2007.
  15.  Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel 
antipsychotic with balanced serotonin-dopamine antagonism, receptor 
occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994; 
55 Suppl:5–12.
  16.  Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared 
with new and reference antipsychotic drugs: in vitro and in vivo 
receptor binding. Psychopharmacology (Berl). 1996;124(1–2): 
57–73.
  17.  Richelson E, Souder T. Binding of antipsychotic drugs to human 
brain receptors focus on newer generation compounds. Life Sci. 2000; 
68(1):29–39.
  18.  Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmaco-
dynamics of the new antipsychotic risperidone. Psychopharmacology 
(Berl). 1994;114(1):9–23.
  19.  Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics, dopamine 
(D2) and serotonin 5HT(2A) receptor occupancy of paliperidone in 
healthy subjects. Clin Pharmacol Ther. 2005;79:P74–P74.
  20.  Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments 
for schizophrenia: a critical review of pharmacology and mecha-
nisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1): 
79–104.
  21.  Corena-McLeod Mdel P, Oliveros A, Charlesworth C, et al. Paliperidone 
as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics 
comparison with lithium and valproic acid after chronic treatment 
reveals similarities in protein expression. Brain Res. 2008;3(1233): 
8–19.
  22.  Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, 
and excretion of paliperidone, a new monoaminergic antagonist, in 
humans. Drug Metab Dispos. 2008;36(4):769–779.
  23.  Cleton A, Rossenu S, Vermeulen A, et al. A pharmacokinetic model 
to document the interconversion between paliperidone’s enantiomers 
[abstract]. Clin Pharmacol Ther. 2006;79(2):55.
  24.  Rossenu S, van de Vliet I, Cleton A, et al. A pharmacokinetic model to 
document the interconversion between the enantiomers of paliperidone 
[abstract]. Biol Psychiatry. 2006;59(8):223S.
  25.  Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic 
impairment on the pharmacokinetics of paliperidone. Int J Clin 
  Pharmacol Ther. 2009;47(10):606–616.
  26.  Dunbar F, Chue P, Fu D, Huang Q, Franc M, Cohen N. Impact of 
CYP2D6 metabolizer phenotype on the safety profile of paliperidone 
ER. The Society of Biological Psychiatry 62nd Annual Scientific 
Convention, San Diego, California, May 17–19, 2007.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
188
Marino et alNeuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2012:8
  27.  Cleton A, Rossenu S, Boom S, et al. Evaluation of the   pharmacokinetics 
of paliperidone extended release tablets in healthy elderly subjects. 
  Presented at the 3rd Pharmaceutical Sciences World Congress. 
  Amsterdam, The Netherlands; 2007.
  28.  Chirita V . A safety and pharmacokinetic study of ER OROS paliperidone 
in pediatric patients with schizophrenia, schizoaffective disorder, 
or schizophreniform disorder. In: ClinicalTrials.gov [website on the 
Internet]. Bethseda, MD: US National Library of Medicine; 2011 
[updated June 6, 2011]. Available from: http://clinicaltrials.gov/ct2/
show/study/NCT00796081. NLM identifier: NCT00796081. Accessed 
March 16, 2012.
  29.  Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine 
on the pharmacokinetics of paliperidone extended-release tablets. 
  Pharmacopsychiatry. 2009;42(4):158–163.
  30.  Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction 
between paliperidone extended-release tablets and trimethoprim in 
healthy subjects. Hum Psychopharmacol. 2009;24(7):532–539.
  31.  De Leon J, Wynn G SN. The pharmacokinetics of paliperidone versus 
risperidone. Psychosomatics. 2010;51(1):80–88.
  32.  Berwaerts J, Xu H, Nuamah I, Lim P, Hough D. Evaluation of the 
efficacy and safety of paliperidone extended-release in the treatment 
of acute mania: a randomized, double-blind, dose-response study.   
J Affect Disord. 2012;136(1–2):e51–e60.
  33.  Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-
controlled study of paliperidone extended release for the treatment of 
acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 
2010;12(3):230–243.
  34.  Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release 
as adjunctive therapy to lithium or valproate in the treatment of acute 
mania: a randomized, placebo-controlled study. J Affect Disord. 2011; 
129(1–3):252–260.
  35.  Canuso CM, Battisti WP. Paliperidone extended-release: a review of 
efficacy and tolerability in schizophrenia, schizoaffective disorder and 
bipolar mania. Expert Opin Pharmacother. 2010;11(15):2557–2567.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
189
Paliperidone for bipolar disorder